Therefore, a combination therapy targeting BRAF together with MEK, a downstream kinase in the same signaling pathway (by using Trametinib or Cobimetinib) was approved in 2015 for stage III and IV melanoma patients [5] increasing the overall survival from approximatively 15 months for single treatments to 25 months and delaying the onset of drug resistance [6, 7]. Here, MAP2K7 is linked to melanoma.